Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ZG-2033 is an agonist of hypoxia-inducible factor 2α (HIF-2α).1 It induces HIF-2α transcriptional activity in a reporter assay using 786-O cells expressing HIF-2α (EC50 = 0.49 µM). ZG-2033 (10 or 50 µM), in combination with the inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3 AKB-6548 (vadadustat; Item No. 15295), increases the number of erythrocytes in a zebrafish model of doxorubicin-induced anemia. It increases the plasma levels of erythropoietin (EPO) in mice when administered at concentrations of 100 or 200 mg/kg in combination with vadadustat.
WARNING This product is not for human or veterinary use.
1. Discovery of a potent and orally bioavailable hypoxia-